2512224-37-0
Chemical Structure
Raloxifene-d10
- CAS No.: 2512224-37-0
- Formula:C28H17D10NO4S
- Molecular Weight:483.64
IUPAC Name: (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl-d10)ethoxy)phenyl)methanone
InChIKey: GZUITABIAKMVPG-VKRZQTKSSA-N
SMILES: O=C(C1=C(C2=CC=C(O)C=C2)SC3=CC(O)=CC=C31)C4=CC=C(OCCN5C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C5([2H])[2H])C=C4
Biological Activity: Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Raloxifene-d10 | Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Raloxifene (Standard) | ≥98% | Raloxifene (Standard) is the analytical standard of Raloxifene. This product is intended for research and analytical applications. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Raloxifene-d4 | Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Raloxifene-d4 hydrochloride | 98.61% | Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Raloxifene | 99.62% | Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
